AI Maverick Intel Inc. has entered into a Right of First Refusal Agreement with HEAL Group Holdings Inc., granting the company the ability to review and match third-party offers for certain HEAL assets or business units under specified conditions. The agreement, effective February 11, 2026, provides AI Maverick Intel with potential acquisition access across HEAL's portfolio of AI-driven healthcare technology and services operating in more than six countries.
In exchange for these rights, AI Maverick Intel will issue 120,000,000 common shares to HEAL at a deemed price of $0.02 per share, representing total consideration of $2.4 million. The arrangement will remain in place for three years unless terminated earlier by mutual agreement between the two companies. This strategic move positions AI Maverick Intel to potentially acquire valuable healthcare technology assets in a rapidly growing sector.
The agreement gives AI Maverick Intel the opportunity to evaluate and potentially acquire HEAL's healthcare technology assets before they become available to other interested parties. HEAL Group's portfolio includes various AI-driven healthcare technologies and services that have established operations across multiple international markets. This right of first refusal allows AI Maverick Intel to strategically position itself in the healthcare technology space without immediate acquisition obligations.
AI Maverick Intel focuses on identifying and developing opportunities at the intersection of artificial intelligence, data platforms, and emerging technology-enabled industries. The company evaluates strategic acquisitions, partnerships, and technology platforms designed to create scalable growth opportunities and long-term shareholder value. The latest news and updates relating to AI Maverick Intel are available in the company's newsroom at http://ibn.fm/AIMV.
The healthcare technology sector has seen significant growth in recent years, particularly in areas involving artificial intelligence applications for medical diagnostics, patient management, and treatment optimization. AI Maverick Intel's agreement with HEAL Group represents a strategic positioning in this expanding market, allowing the company to potentially acquire established technologies and services without immediate financial commitment beyond the share issuance. The three-year term provides flexibility for both companies while ensuring AI Maverick Intel maintains priority access to these assets should HEAL decide to sell them to third parties.
